{
  "meta": {
    "title": "44_Anti-Virals_Non-Retroviral",
    "url": "https://brainandscalpel.vercel.app/44-anti-virals-non-retroviral-b5c43cf7.html",
    "scrapedAt": "2025-11-30T12:34:27.188Z"
  },
  "questions": [
    {
      "text": "A 54-year-old man was brought to the casualty with fever, headache, focal seizures, and right hemiparesis. MRI brain showed hyperintensity in the left frontotemporal region. PCR of his CSF sample was positive for HSV DNA. What would be the drug of choice for this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Valacyclovir"
        },
        {
          "id": 2,
          "text": "Acyclovir"
        },
        {
          "id": 3,
          "text": "Gancyclovir"
        },
        {
          "id": 4,
          "text": "Foscarnet"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario and investigations are suggestive of <strong>HSV encephalitis</strong> for which the drug of choice is <strong>intravenous acyclovir</strong>. The treatment is effective only if it is started early.</p>\n<p>The clinical hallmark of HSV encephalitis is the acute onset of fever and focal neurologic signs with hemorrhagic necrosis of especially the <strong>temporal lobe</strong>. The most sensitive investigation is HSV DNA demonstration in CSF by <strong>PCR</strong>. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6467",
      "difficulty": "easy"
    },
    {
      "text": "A patient diagnosed with shingles was prescribed acyclovir. Which of the following statements is false regarding this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Acyclovir is a nucleoside congener"
        },
        {
          "id": 2,
          "text": "Nephrotoxicity is a dose limiting side effect of acyclovir"
        },
        {
          "id": 3,
          "text": "Valacyclovir has a higher bioavailability than acyclovir"
        },
        {
          "id": 4,
          "text": "Acyclovir does not enter the CSF"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Acyclovir <strong>can enter CSF</strong> as it is widely distributed into all body fluid compartments, including vesicular fluid and aqueous humor. It can be used for treating shingles caused by HZV.</p>\n<p>Option A: Acyclovir is a <strong>guanosine </strong>nucleoside congener. The other nucleoside congeners are cidofovir, ganciclovir, and famciclovir.</p>\n<p>Option B:<strong> Nephrotoxicity</strong> and<strong> neurotoxicity</strong>, though rare and reversible, are <strong>dose-limiting </strong>side effects of acyclovir.</p>\n<p>Option C: Acyclovir has a low bioavailability which is overcome by administering <strong>valacyclovir</strong>, a prodrug with <strong>higher bioavailability</strong>.</p>\n<p>Mechanism of action of anti-viral drugs:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/90a29df15d924ea084eb85bb747cb5c4x1280x1406.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6470",
      "difficulty": "easy"
    },
    {
      "text": "What is the most common cause of resistance to acyclovir in HSV-1?",
      "choices": [
        {
          "id": 1,
          "text": "Induction of efflux pumps"
        },
        {
          "id": 2,
          "text": "Mutation of viral DNA polymerase"
        },
        {
          "id": 3,
          "text": "Deficient viral thymidine kinase activity"
        },
        {
          "id": 4,
          "text": "Expression of inactivating enzymes"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The most common cause of resistance to acyclovir in HSV-1 is<strong> deficient </strong>or<strong> absent viral thymidine kinase </strong>activity.</p>\n<p>Viral thymidine kinase is needed in the <strong>conversion of acyclovir</strong> to acyclovir triphosphate which competitively inhibits the viral DNA polymerase activity.  </p>\n<p>Mutation of viral DNA polymerase is rare.</p>\n<p>Mechanism of action of anti-viral drugs:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ed5c8c53b9274a568dc382eba1a70f66x1280x1406.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4177",
      "difficulty": "medium"
    },
    {
      "text": "In which of the following patients can valacyclovir be used as the drug of choice?",
      "choices": [
        {
          "id": 1,
          "text": "An elderly woman with avian influenza"
        },
        {
          "id": 2,
          "text": "An infant with RSV bronchiolitis"
        },
        {
          "id": 3,
          "text": "An adolescent with chickenpox"
        },
        {
          "id": 4,
          "text": "An immunocompromised patient with CMV retinitis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Oral valacyclovir</strong> 1g three times daily for 5-7 days is considered the drug of choice for <strong>chickenpox (VZV)&nbsp;</strong>in an immunocompetent patient. Treatment should be started ideally <strong>within 24 hours</strong> of rash onset.</p>\n<p>Oral acyclovir (800 mg five times daily) is an alternative drug, but valacyclovir is preferred due to its <strong>higher bioavailability </strong>and less frequent dosing.&nbsp;In immunocompromised patients, varicella infection is treated with IV acyclovir.</p>\n<p>Option A: <strong>Oseltamivir</strong> is used for the treatment of avian influenza.</p>\n<p>Option B: <strong>Ribavirin</strong> is used for treating RSV bronchiolitis.</p>\n<p class=\"p1\">Option D: Ganciclovir, foscarnet, and cidofovir are approved for CMV retinitis.</p><p class=\"p1\">Hematopoietic stem cell transplant recipients are given <strong>prophylaxis</strong> against <strong>CMV</strong> infections with <strong>letermovir</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6468",
      "difficulty": "medium"
    },
    {
      "text": "A patient showed persistence of genital herpes lesions even after 7 days of high-dose oral acyclovir therapy. Which of the following antivirals can you use to manage this case?",
      "choices": [
        {
          "id": 1,
          "text": "Ganciclovir"
        },
        {
          "id": 2,
          "text": "Abacavir"
        },
        {
          "id": 3,
          "text": "Foscarnet"
        },
        {
          "id": 4,
          "text": "Valacyclovir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Intravenous <strong>foscarnet</strong> is used to treat <strong>acyclovir-resistant</strong> <strong>HSV</strong> (genital herpes) and <strong>VZV</strong> infections.</p>\n<p>It<strong>&nbsp;</strong>inhibits viral nucleic acid synthesis<strong>&nbsp;</strong>by <strong>directly&nbsp;inhibiting HSV DNA polymerase </strong>(or HIV reverse transcriptase).&nbsp;It is active against&nbsp;herpes simplex, CMV, VZV,&nbsp;and&nbsp;HIV.</p>\n<p>Metabolic abnormalities are very common with foscarnet. Symptomatic <strong>hypocalcemia </strong>and<strong> nephrotoxicity</strong> are major <strong>dose-limiting</strong> toxicities of foscarnet.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4180",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a true statement about amantadine?",
      "choices": [
        {
          "id": 1,
          "text": "The most common side effect is CNS toxicity"
        },
        {
          "id": 2,
          "text": "It is effective only against Influenza B"
        },
        {
          "id": 3,
          "text": "It is routinely used for the treatment of influenza"
        },
        {
          "id": 4,
          "text": "It is largely metabolised by the liver"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most common side effect of amantadine is <strong>minor CNS toxicity</strong> which includes&nbsp;nervousness, difficulty concentrating, and insomnia. It&nbsp;is effective only against<strong> Influenza A</strong>.</p>\n<p>Most strains of influenza are now resistant to amantadine and hence, it is&nbsp;<strong>not routinely used</strong> for the treatment or prophylaxis of influenza infections. Amantadine&nbsp;is largely excreted<strong> unmetabolized </strong>in the <strong>urine</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6471",
      "difficulty": "hard"
    },
    {
      "text": "A young woman with a recent travel history presented with fever and respiratory difficulty. She was diagnosed with Influenza A and was started on oseltamivir. What is the mechanism of action of this drug?",
      "choices": [
        {
          "id": 1,
          "text": "DNA polymerase inhibition"
        },
        {
          "id": 2,
          "text": "Protein synthesis inhibition"
        },
        {
          "id": 3,
          "text": "Nucleoside analogue"
        },
        {
          "id": 4,
          "text": "Neuraminidase inhibition"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Oseltamivir is a <strong>neuraminidase inhibitor.</strong></p>\n<p>Drugs like oseltamivir and zanamivir competitively and reversibly interact with the enzyme sites to inhibit viral neuraminidase activity. This interferes with the release of the progeny from infected host cells, halting the spread of infection.</p>\n<p>Early administration&nbsp;<span class=\"fontstyle0\">hastens the resolution of symptoms if given within 48 h of infection. O</span>seltamivir is given at a dose of <strong>75 mg, twice a day for 5 days</strong> for the <strong>treatment</strong> of influenza A and B. For prophylaxis, it is given at a dose of <strong>75mg, once per day,</strong> and continued for the duration of exposure.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0191",
      "difficulty": "easy"
    },
    {
      "text": "Zanamivir is to be given for a patient with an influenza B infection. How will you administer this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Oral route"
        },
        {
          "id": 2,
          "text": "Inhalational route"
        },
        {
          "id": 3,
          "text": "Intravenous route"
        },
        {
          "id": 4,
          "text": "Intramuscular route"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Zanamivir is delivered by oral <strong>inhalation </strong>of dry powder in a lactose carrier. Its oral bioavailability is very low (&lt;5%).</p>\n<p>Zanamivir is a neuraminidase inhibitor similar to oseltamivir and is active against both <strong>influenza A and B</strong>.</p>\n<p>The different routes of administration of neuraminidase inhibitors are as follows:</p>\n<ul>\n<li>Zanamivir: Inhalational</li>\n<li>Oseltamivir: Oral</li>\n<li>Peramivir: Intravenous</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6474",
      "difficulty": "easy"
    },
    {
      "text": "A 22-year-old man is admitted with acute H1N1 influenza pneumonia. He is having severe nausea and vomiting and is not able to take any oral medications. Which of the following drugs can be administered intravenously to him?",
      "choices": [
        {
          "id": 1,
          "text": "Oseltamivir"
        },
        {
          "id": 2,
          "text": "Zanamivir"
        },
        {
          "id": 3,
          "text": "Peramivir"
        },
        {
          "id": 4,
          "text": "Entecavir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Peramivir</strong> is a neuraminidase inhibitor available for <strong>intravenous </strong>administration for acute influenza (H1N1).</p>\n<p>It is indicated in acute influenza infections where the patient is not able to take drugs via the oral route or if inhalational (zanamivir) formulation is unavailable.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6475",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old man, who has history of contact with a known case of influenza, is having fever, cough, and runny nose since today morning. Rapid antigen test turns out to be positive. The endonuclease inhibitor that can be used for his treatment is ___________.",
      "choices": [
        {
          "id": 1,
          "text": "Oseltamivir"
        },
        {
          "id": 2,
          "text": "Baloxavir"
        },
        {
          "id": 3,
          "text": "Zanamivir"
        },
        {
          "id": 4,
          "text": "Favipravir"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>endonuclease</strong> <strong>inhibitor</strong> which can be used for the treatment of acute uncomplicated influenza in adults is <strong>baloxavir marboxil.</strong></p>\n<p>It is a novel drug that was approved by the FDA in 2018. It is used to treat acute&nbsp;<strong>uncomplicated influenza</strong> in patients <strong>12 years </strong>of age<strong> and older</strong> who have been symptomatic for <strong>less than 48 hours. </strong></p>\n<p>It is a <strong>selective inhibitor </strong>of influenza cap-dependent<strong> endonuclease</strong> which blocks proliferation by inhibiting mRNA synthesis.</p><p><strong>Recent Update</strong>: In 2020, the FDA expanded the approved indication for baloxavir marboxil (Xofluza) to include <strong>post-exposure prevention of influenza</strong> (flu) for patients 12 years of age and older after contact with an individual who has the flu.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9672",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is approved for prophylaxis against respiratory syncytial virus (RSV) infection?",
      "choices": [
        {
          "id": 1,
          "text": "Omalizumab"
        },
        {
          "id": 2,
          "text": "Palivizumab"
        },
        {
          "id": 3,
          "text": "Denosumab"
        },
        {
          "id": 4,
          "text": "Ribavirin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Palivizumab</strong> is a monoclonal antibody approved for <strong>prophylaxis</strong> against respiratory syncytial virus (RSV) infection.</p>\n<p>It is a humanized monoclonal antibody against F-glycoprotein present on the surface of RSV. It is used in <strong>high-risk infants </strong>(prematurity and immunosuppressed conditions)<strong>&nbsp;</strong>and<strong> children</strong>&nbsp;(with cardiovascular and pulmonary diseases).</p>\n<p>The <strong>treatment</strong> of RSV infections is done with <strong>inhaled ribavirin</strong>.</p>\n<p>Option A: Omalizumab is a monoclonal antibody against IgE indicated in asthma.</p>\n<p>Option C: Denosumab is a monoclonal antibody against RANKL indicated in osteoporosis.</p>\n<p>Option D: Ribavirin is used for treatment of RSV infections but is not approved for prophylaxis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6478",
      "difficulty": "medium"
    },
    {
      "text": "A hepatitis B infected patient awaiting liver transplantation is admitted with ascites and encephalopathy. Which of the following is the drug of choice for him?",
      "choices": [
        {
          "id": 1,
          "text": "Interferon alpha"
        },
        {
          "id": 2,
          "text": "Lamivudine"
        },
        {
          "id": 3,
          "text": "Tenofovir"
        },
        {
          "id": 4,
          "text": "Telbivudine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario of <strong>ascites</strong> and <strong>encephalopathy</strong> in a hepatitis B infected patient is suggestive of <strong>decompensated liver disease</strong>. <strong>Tenofovir</strong> is the <strong>drug of choice</strong> for decompensated cirrhosis due to hepatitis B infection.</p>\n<p>Tenofovir<strong> </strong>is one of the <strong>first-line</strong> drugs for chronic hepatitis B infections. It is available as two prodrug formulations tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).</p>\n<p>Option A: Interferon-alpha is one of the first-line agents in individuals with<strong> ongoing HBV-DNA replication</strong> and liver inflammation. But it is <strong>contraindicated in decompensated cirrhosis</strong> with HBV infection as they can precipitate clinical deterioration and increase the risk of bacterial infections.  </p>\n<p>Options B and D: Lamivudine and Telbivudine are not considered first-line agents for HBV infections because of the increased frequency of resistance associated with their use.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4182",
      "difficulty": "medium"
    },
    {
      "text": "Sofosbuvir is indicated in the treatment of which of the following patients?<div class='question-desc-html'><ol>\n<li>A 33-year-old man with post-transfusion hepatitis B</li>\n<li>A 47-year-old man with symptomatic chronic hepatitis C</li>\n<li>A 24-year-old man with hepatitis B and D coinfection</li>\n<li>A 52-year-old woman with hepatitis B and D superinfection</li>\n<li>A 42-year-old woman with asymptomatic chronic hepatitis C</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1 and 2 only"
        },
        {
          "id": 2,
          "text": "1 and 3 only"
        },
        {
          "id": 3,
          "text": "2 and 5 only"
        },
        {
          "id": 4,
          "text": "2, 3 and 4 only"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Sofosbuvir is indicated in the treatment of&nbsp;<strong>hepatitis C</strong> infection only. It is a directly acting antiviral,<strong> NS5B</strong> nucleotide polymerase inhibitor.</p>\n<p>The goal of treatment in hepatitis C is a <strong>sustained virologic response</strong> (SVR). It is defined as the absence of a virus in the blood (undetectable HCV RNA), 12 weeks after completion of treatment. This can be achieved by the use of<strong> pan-genotypic</strong> directly acting antiviral drugs, irrespective of the disease stage.</p><hr><h3>Related Pearl: Direct acting antivirals (DAA) - Drugs against Hepatitis-C virus</h3><p>The directly acting antivirals used in the treatment of Hepatitis C infection include:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Mechanism of action&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>Example</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5A inhibitors (asvir)</p>\n</td>\n<td>\n<ul>\n<li><strong>Velpatasvir</strong></li>\n<li>Daclatasvir</li>\n<li>Ledipasvir</li>\n<li>Ombitasvir</li>\n<li>Elbasvir</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5B nucleos(t)ide polymerase inhibitor (buvir)</p>\n</td>\n<td>\n<ul>\n<li><strong>Sofosbuvir</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5B non nucleos(t)ide polymerase inhibitor (buvir)</p>\n</td>\n<td>\n<ul>\n<li>Dasabuvir</li>\n<li>Beclabuvir</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS3/4A inhibitors (previr)</p>\n</td>\n<td>\n<ul>\n<li>Boceprevir</li>\n<li>Telaprevir</li>\n<li>Simeprevir</li>\n<li>Paritaprevir</li>\n<li>Asunaprevir</li>\n<li>Grazoprevir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;The following combinations of antiviral drugs can be used:</p>\n<ul>\n<li aria-level=\"1\">Acute, chronic hepatitis, or compensated cirrhosis:\n<ul>\n<li>Velpatasvir (NS5A Inhibitor) + Sofosbuvir (NS5B inhibitor) x 12 weeks.</li>\n</ul>\n</li>\n<li aria-level=\"1\">Decompensated cirrhosis:\n<ul>\n<li>Velpatasvir (NS5A Inhibitor) + Sofosbuvir (NS5B inhibitor) + Ribavirin (syntheticnucleotide analogue) x 12 weeks.</li>\n</ul>\n</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB6477",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a direct-acting agent (DAAs) used in the treatment of HCV infections?",
      "choices": [
        {
          "id": 1,
          "text": "NS5B polymerase inhibitors"
        },
        {
          "id": 2,
          "text": "NS5A inhibitors"
        },
        {
          "id": 3,
          "text": "NS3/4A protease inhibitors"
        },
        {
          "id": 4,
          "text": "NS4B inhibitors"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>NS4B inhibitors are <strong>not</strong> direct-acting agents (DAAs).</p>\n<p>Direct-acting agents (DAAs) are drugs that <strong>target specific viral proteins</strong> which are vital to the <strong>replication </strong>and<strong> lifecycle</strong> of <strong>HCV</strong>.</p>\n<p>The <strong>currently available DAAs</strong> inhibit 3 specific non-structural (NS) proteins:</p>\n<ul>\n<li>\n<p>NS3/4A protease inhibitors</p>\n</li>\n<li>\n<p>NS5A inhibitors</p>\n</li>\n<li>\n<p>NS5B polymerase inhibitors &nbsp;</p>\n</li>\n</ul><hr><h3>Related Pearl: Direct acting antivirals (DAA) - Drugs against Hepatitis-C virus</h3><p>The directly acting antivirals used in the treatment of Hepatitis C infection include:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Mechanism of action&nbsp;</strong></p>\n</td>\n<td>\n<p><strong>Example</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5A inhibitors (asvir)</p>\n</td>\n<td>\n<ul>\n<li><strong>Velpatasvir</strong></li>\n<li>Daclatasvir</li>\n<li>Ledipasvir</li>\n<li>Ombitasvir</li>\n<li>Elbasvir</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5B nucleos(t)ide polymerase inhibitor (buvir)</p>\n</td>\n<td>\n<ul>\n<li><strong>Sofosbuvir</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS5B non nucleos(t)ide polymerase inhibitor (buvir)</p>\n</td>\n<td>\n<ul>\n<li>Dasabuvir</li>\n<li>Beclabuvir</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p>NS3/4A inhibitors (previr)</p>\n</td>\n<td>\n<ul>\n<li>Boceprevir</li>\n<li>Telaprevir</li>\n<li>Simeprevir</li>\n<li>Paritaprevir</li>\n<li>Asunaprevir</li>\n<li>Grazoprevir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;The following combinations of antiviral drugs can be used:</p>\n<ul>\n<li aria-level=\"1\">Acute, chronic hepatitis, or compensated cirrhosis:\n<ul>\n<li>Velpatasvir (NS5A Inhibitor) + Sofosbuvir (NS5B inhibitor) x 12 weeks.</li>\n</ul>\n</li>\n<li aria-level=\"1\">Decompensated cirrhosis:\n<ul>\n<li>Velpatasvir (NS5A Inhibitor) + Sofosbuvir (NS5B inhibitor) + Ribavirin (syntheticnucleotide analogue) x 12 weeks.</li>\n</ul>\n</li>\n</ul>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4185",
      "difficulty": "medium"
    },
    {
      "text": "A 52-year-old woman with history of hepatitis B infection presents with fatigue, vomiting, and weight loss. Her serological markers are given in the table below. What is the treatment of choice for her condition?<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>Diagnostic markers</td>\n<td>Result</td>\n</tr>\n<tr>\n<td>HBsAg</td>\n<td>+</td>\n</tr>\n<tr>\n<td>IgM Anti-HBc</td>\n<td>-</td>\n</tr>\n<tr>\n<td>HDAg</td>\n<td>-</td>\n</tr>\n<tr>\n<td>HDV RNA&nbsp;</td>\n<td>+</td>\n</tr>\n<tr>\n<td>IgG Anti-HDV</td>\n<td>+</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "Paritaprevir booster with ritonavir"
        },
        {
          "id": 2,
          "text": "Pegylated interferon-alpha"
        },
        {
          "id": 3,
          "text": "Velpatasvir + Voxilaprevir + Sofosbuvir"
        },
        {
          "id": 4,
          "text": "Tenofovir + Entecavir"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given scenario and serology are suggestive of <strong>chronic hepatitis D infection</strong>&nbsp;in a hepatitis B carrier for which the treatment of choice is&nbsp;<strong>pegylated interferon-alpha</strong> (pegIFN-<span>&alpha;</span>).</p>\n<p>It is the only drug currently available to treat chronic hepatitis D infection.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4192",
      "difficulty": "medium"
    },
    {
      "text": "A young woman presents with painless warty lesions on the vulva as shown in the image below. Which of the following is a topical agent that can be prescribed for her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Docosanol"
        },
        {
          "id": 2,
          "text": "Nystatin"
        },
        {
          "id": 3,
          "text": "Imiquimod"
        },
        {
          "id": 4,
          "text": "Acyclovir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Warty lesions on the vulva as seen in the given image is suggestive of <strong>condyloma acuminata </strong>caused by <strong>HPV</strong> (6, 11)<strong>. Imiquimod </strong>is a<strong> topical&nbsp;</strong>agent with antiviral and immunomodulatory properties indicated in the treatment of external genital and perianal warts.</p>\n<p>Other topical agents that can be used include&nbsp;podophyllotoxin and trichloroacetic acid.&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c8066293e7f1477da782821d1de724de.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB7793",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is currently approved for the treatment of small pox?",
      "choices": [
        {
          "id": 1,
          "text": "Tecovirimat"
        },
        {
          "id": 2,
          "text": "Lumacaftor"
        },
        {
          "id": 3,
          "text": "Pegvaliase"
        },
        {
          "id": 4,
          "text": "Apalutamide"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Tecovirimat</strong>&nbsp;has been recently approved as a <strong>treatment of smallpox</strong>.</p>\n<p>It was <strong>approved under the FDA's animal rule</strong>, which allows findings from animal studies to support an FDA approval when it is not feasible or ethical to conduct efficacy trials in humans.&nbsp;Cidofovir has also been approved by the FDA for smallpox under this rule.</p>\n<p>Both these drugs are currently stockpiled by CDC&rsquo;s strategic national stockpile, which has the medical supplies required to protect the public in case of a public health emergency.</p>\n<p>Tecovirimat could also be used under an investigational new drug (IND) protocol to<strong> treat</strong> <strong>adverse reactions from vaccinia</strong> vaccination.</p>\n<p>Option B:&nbsp;<strong>Lumacaftor </strong>is a drug approved for<strong>&nbsp;cystic fibrosis.</strong></p>\n<p>Option C:&nbsp;<strong>Pegvaliase</strong> has been approved for the treatment of<strong> phenylketonuria</strong> in adults.</p>\n<p>Option D:&nbsp;<strong>Apalutamide</strong> is a nonsteroidal <strong>antiandrogen</strong> medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of <strong>non-metastatic castration-resistant prostate cancer.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5665",
      "difficulty": "hard"
    }
  ]
}